Scientists Edited Human Embryos in the Lab, and It Was a Disaster
By Emily Mullin,
OneZero
| 06. 15. 2020
The experiment raises major safety concerns for gene-edited babies
A team of scientists has used the gene-editing technique CRISPR to create genetically modified human embryos in a London lab, and the results of the experiment do not bode well for the prospect of gene-edited babies.
Biologist Kathy Niakan and her team at the Francis Crick Institute wanted to better understand the role of a particular gene in the earliest stages of human development. So, using CRISPR, they deleted that gene in human embryos that had been donated for research. When they analyzed the edited embryos and compared them to ones that hadn’t been edited, they found something troubling: Around half of the edited embryos contained major unintended edits.
“There’s no sugarcoating this,” says Fyodor Urnov, a gene-editing expert and professor of molecular and cell biology at the University of California, Berkeley. “This is a restraining order for all genome editors to stay the living daylights away from embryo editing.”
While the embryos were not grown past 14 days and were destroyed after the editing experiment, the results provide a warning for future attempts to establish pregnancies with genetically modified...
Related Articles
By Emily Mullin, Wired | 11.14.2023
In a small initial test in people, researchers have shown that a single infusion of a novel gene-editing treatment can reduce cholesterol, the fatty substance that clogs and hardens arteries over time.
The gene-editing treatment aims to permanently lower cholesterol...
By Carissa Wong, Nature | 11.16.2023
In a world first, the UK medicines regulator has approved a therapy that uses the CRISPR–Cas9 gene-editing tool as a treatment. The decision marks another high point for a biotechnology that has been lauded as revolutionary in the decade since...
By Emily Mullin, Wired | 11.16.2023
The first medical treatment that uses Crispr gene editing was authorized Thursday by the United Kingdom.
The one-time therapy, which will be sold under the brand name Casgevy, is for patients with sickle cell disease and a related blood disorder...
By Alexis Heng, UCA News | 11.13.2023
In recent years, Singapore has increasingly leveraged new reproductive technologies to overcome the country's rapidly aging demographics and dismal fertility rate, which hit a new low in 2022.
Hence, it would be timely for Singapore’s Bioethics Advisory Committee (BAC) to...